The U.S. filed a lawsuit against Regeneron Pharmaceuticals, alleging the New York-based drugmaker of inflating Medicare reimbursement rates for Eylea, the Justice Department said.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
